To date, only a few studies have reported on MYC and BCL2 co-expression in relapsed or refractory DLBCL [83,84], and therefore the prognostic value of double expressor status in this setting remains uncertain. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.